JBaids was selected by the US Department of Defense as the platform for use in rapid identification of over ten deadly pathogens associated with bioterrorism and diseases of military interest.
The US Food and Drug Administration (FDA) has approved Idaho Technology's Joint Biological Agent Identification and Diagnostic System (JBaids) for use in clinical diagnosis of Bacillus anthracis, the deadly organism that causes anthrax infections.
The FDA approval is for testing blood and blood culture samples to aid in clinical diagnosis of anthrax in less than one hour.
The current method such as growing a culture can take as long as several days for results.
"This is a great example of how private industry and the government can work as partners to protect our nation and those whom defend it.
"Our team which consisted of the FDA, the Joint Program Executive Office for Chemical and Biological Defense particularly the Chemical and Biological Medical Systems Division, and scientists and staff at Idaho Technology worked extremely hard and effectively to get the system approved, providing a capability to make our servicemen and woman safer," says Todd Ritter, Idaho Technology's chief corporate development officer.
"We would also like to thank the US Army, Navy and Air Force laboratories that performed the clinical trials, as this was truly a joint effort".
